FDA panel recommends EUA for Moderna’s COVID-19 vaccine candidate
The Food and Drug Administration’s Vaccines and Related Biological Products Advisory Committee Dec. 17 recommended the approval of Moderna’s mRNA-1273 COVID-19 vaccine candidate.
The panel voted 20-0, with one abstention, that FDA issue an emergency use authorization.
Once the EUA is issued by the FDA, which could happen as soon as today, Operation Warp Speed expects to begin shipping immediately to U.S. hospitals and other sites as designated by state and jurisdictional leaders. The vaccine is administered in two doses 28 days apart.
Related News Articles
Headline
The Centers for Disease Control and Prevention's COVID-19 data tracker shows an 18.1% test positivity rate for the week ending Aug. 10, the highest it has been…
Headline
The Centers for Disease Control and Prevention Aug. 13 issued an advisory alerting of an uptick of cases of parvovirus B19 across the U.S. Parvovirus B19 is a…
Headline
Adults age 65 and older are encouraged to receive an updated dosage of the COVID-19 vaccine, the Centers for Disease Control and Prevention announced April 25…
Headline
The Pfizer and Moderna COVID-19 vaccines can cause myocarditis, but do not appear to cause infertility, Guillain-Barré syndrome, Bell’s palsy, thrombosis with…
Headline
Centers for Disease Control and Prevention Director Mandy Cohen, M.D., Feb. 28 endorsed a recommendation by its Advisory Committee on Immunization Practices…
Headline
Paxlovid may no longer be distributed with an emergency use label after March 8, the Food and Drug Administration announced. Providers may dispense unexpired…